Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Updates on immunotherapy options for metastatic urothelial carcinoma

Kirollos Hanna • 21 Mar 2018
HOPA 2018
Bladder Cancer Genitourinary Cancer Atezolizumab Pembrolizumab
IMvigor210 KEYNOTE-045

New and exciting developments on urothelial cancer were presented at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. In this detailed interview, Kirollos Hanna, PharmD, BCOP, BCPS of the University of Minnesota Medical Center, Minneapolis, MN, discusses PD-L1 expression and covers the latest updates on immunotherapy options for metastatic urothelial carcinoma.

More from Kirollos Hanna

1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna • 21 Mar 2018
1:29
Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community
Kirollos Hanna • 21 Mar 2018
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna • 21 Mar 2018
2:12
Looking towards the future: what is in store for the treatment of bladder cancer?
Kirollos Hanna • 21 Mar 2018

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals